GASTRIC / GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Clinical trials for GASTRIC / GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new GASTRIC / GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for GASTRIC / GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Can a double immunotherapy beat standard care for a tough stomach cancer?
Disease control Recruiting nowThis phase II trial is comparing a new combination of two immunotherapies (iparomlimab and tuvonralimab) against standard chemotherapy plus a PD-1/PD-L1 inhibitor as a first-line treatment for people with recurrent or metastatic gastric cancer that is MSI-H or dMMR. The study aim…
Matched conditions: GASTRIC / GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Peking University • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
Can a Two-Target antibody shrink Hard-to-Treat cancers?
Disease control Recruiting nowThis trial is testing an experimental drug called petosemtamab (MCLA-158) in people with advanced solid tumors, including colorectal, head and neck, and lung cancers. The drug is a bispecific antibody designed to block two cancer-related proteins, EGFR and LGR5. Researchers want …
Matched conditions: GASTRIC / GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Merus B.V. • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
New drug combo trial aims to fight advanced cancers
Disease control Recruiting nowThis study tests a new drug called BMS-986340, alone or with other cancer treatments, in people with advanced solid tumors like lung, colon, or breast cancer. The goal is to find safe doses and check for side effects. About 1,100 adults with tumors that have worsened after standa…
Matched conditions: GASTRIC / GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New drug combo aims to outsmart Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase study tests an experimental drug called OKN4395, taken as a pill, alone or together with the immunotherapy pembrolizumab. The goal is to find a safe dose and see if the combination can shrink tumors in people with advanced solid cancers like lung, colorectal, sto…
Matched conditions: GASTRIC / GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE1 • Sponsor: Epkin • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New drug combo targets Hard-to-Treat cancers
Disease control Recruiting nowThis phase 2 study tests a new drug called IBI343 combined with two chemotherapy drugs (gemcitabine and nab-paclitaxel) in people with advanced stomach, gastroesophageal junction, or pancreatic cancers that have a specific protein (CLDN18.2). The goal is to see if the combination…
Matched conditions: GASTRIC / GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Innovent Biologics (Suzhou) Co. Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New Antibody-Drug conjugate KIVU-107 enters first human trials for Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage trial tests a new drug called KIVU-107 in 76 adults with advanced solid tumors that have not responded to standard treatments. KIVU-107 is an antibody-drug conjugate designed to target and kill cancer cells. The main goal is to find a safe dose and check for side…
Matched conditions: GASTRIC / GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE1 • Sponsor: Kivu Bioscience Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC